Effect of Unani drug on high blood pressure

Efficacy of Arjun Ch Ä?l as adjunct in Essential Hypertension: A Randomized controlled study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/03/041534

Enrollment

Registered

2022-03-31

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Arjun Ch Ä?l (Terminalia Arjuna): Fine powder of Arjun Chhal 3gm will be given orally in capsules, daily in two divided doses. Control Intervention1: Roasted wheat flour: Placebo (roas

Eligibility

Inclusion criteria

Inclusion criteria: Patients using Angiotensin II Receptor Blockers (ARB) will be included in the study Patient with stage 1 hypertension (Systolic140-159 mmHg and Diastolic90-99mmHg)

Exclusion criteria

Exclusion criteria: Secondary hypertension Known case of congestive heart failure. Essential hypertension with Diabetes Mellitus Essential hypertension with ischemic heart disease Essential hypertension with chronic renal failure Pregnant & lactating mothers Patients using antihypertensive other than Angiotensin II Receptor Blockers Significant liver or renal dysfunction A medical condition that in the investigator opinion would interfere with treatment safety or adherence to the protocol

Design outcomes

Primary

Measure	Time frame
Reduction in Systolic and Diastolic blood pressureTimepoint: 28 days	—

Secondary

Measure	Time frame
Improvement in subjective parameters. Changes in lipid profile (S. Cholesterol, S. triglycerides and LDL) Timepoint: 28 days	—

Countries

India

Contacts

Public ContactDr Muzaffar Din Ahmad Bhat

National Institute of Unani Medicine

drmuzaffar79@gmail.com9590366192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026